Pellet Technology Study
The following case study highlights how use of Pellet technology reduces the symptoms of nausea and provides patients with smooth steady-state plasma levels.
The mode of action of delayed release pellets can be demonstrated as follows;
- Enteric coated capsule dissolves and releases approximately 300 coated pellets. The pellets which are resistant to the gastric juice due to the polymer coating, are gradually distributed in the stomach.
- Because of their small size, the pellets pass easily through the pylorus. The specific milieu of the duodenum with pH levels 6-7, causes the enteric-coating to disintegrate, and the active pharmaceutical ingredient is rapidly absorbed.
The following graph demonstrates that compared to Vibramycin™, which is supplied in a conventional capsule formulation, controlled-release pharmaceutical Doryx™, supplied in pellet form, significantly reduces the effects of nausea.
Incidence of nausea induced by Vibramycin™ 100mg, Doryx™ 100mg capsules and placebo
Benefits of pellet technology are further showcased through a trial with Kapanol™ / Kadian™ capsules, whose drug delivery profile is achieved with Mayne Pharma’s sustained release pellet technology, and provides patients with smooth steady-state plasma levels for consistent pain relief compared to morphine in either a controlled release tablet or oral solution form.
Mean steady state plasma morphine concentrations for Kapanol™ / Kadian™ capsules, controlled release morphine tablet and oral morphine solution.
Please note this information is intended for potential licensees.